Literature DB >> 23247829

Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America.

Edyta Sutkowska1, Robert D McBane, Alfonso J Tafur, Krzysztof Sutkowski, Diane E Grill, Joshua P Slusser, Waldemar E Wysokinski.   

Abstract

BACKGROUND: The utility of thrombophilia testing in patients with splanchnic vein thrombosis (SpVT) has not previously been rigorously evaluated. The purpose of this study was to characterize differences in the prevalence of thrombophilia in patients with SpVT involving portal (PVT), mesenteric (MVT), splenic (SVT), or hepatic (HVT) veins in isolation or with multisegmental (M-SpVT) involvement compared to patients with lower extremity deep vein thrombosis (DVT).
METHODS: An inception cohort of patients with incident SpVT was identified for whom comprehensive thrombophilia testing was performed between 1995 and 2005 and compared to DVT controls.
RESULTS: 341 patients with SpVT (mean age 50 ± 16 years, 53 % women) including isolated PVT (n = 112), MVT (n = 67), HVT (n = 22), SVT (n = 11), and M-SpVT (n = 129) involvement and 3621 DVT controls (mean age 55 ± 16 years, 56 % women) had comprehensive thrombophilia testing. The prevalence of abnormal results was similar for SpVT (24.6 %) and DVT (25.9 %) patients. "Strong" thrombophilias were more prevalent among SpVT patients (12.3 vs. 8.5 %, p = 0.0168). Patients with splenic (45.5 %) and mesenteric (41.8 %) thrombosis had the highest thrombophilia prevalence. Protein S deficiency was more common in SpVT patients (3.5 vs. 0.9 %, p < 0.001). In contrast, FV Leiden was more prevalent among DVT patients (15.8 vs. 10.9 %, p = 0.0497).
CONCLUSION: The prevalence of selected thrombophilia factors differ comparing SpVT and DVT patients. The prevalence is particularly high for patients with splenic and mesenteric vein thrombosis. Whereby the finding of strong thrombophilia impacts duration of anticoagulant therapy, such testing is warranted in the evaluation of patients with unprovoked SpVT.

Entities:  

Mesh:

Year:  2012        PMID: 23247829     DOI: 10.1007/s00535-012-0728-3

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Extra-hepatic synthesis of protein S.

Authors:  H P Schwarz
Journal:  Thromb Haemost       Date:  1990-10-22       Impact factor: 5.249

2.  Factor V Leiden related Budd-Chiari syndrome.

Authors:  P Deltenre; M H Denninger; S Hillaire; M C Guillin; N Casadevall; J Brière; S Erlinger; D C Valla
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

3.  Risk factors for thrombophilia in extrahepatic portal vein obstruction.

Authors:  Massimo Primignani; Ida Martinelli; Paolo Bucciarelli; Tullia Battaglioli; Raffaella Reati; Federica Fabris; Alessandra Dell'era; Emanuela Pappalardo; Pier Mannuccio Mannucci
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

4.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

5.  Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.

Authors:  A E Mahmoud; E Elias; N Beauchamp; J T Wilde
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

6.  Thrombophilia: 2009 update.

Authors:  Pat Foy; Stephan Moll
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

7.  Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience.

Authors:  Rupesh Rajani; Tor Melin; Einar Björnsson; Ulrika Broomé; Per Sangfelt; Ake Danielsson; Anders Gustavsson; Olof Grip; Hans Svensson; Lars Lööf; Sven Wallerstedt; Sven H C Almer
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

8.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

Review 9.  The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

Authors:  Antonio Marchiori; Laura Mosena; Martin H Prins; Paolo Prandoni
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

10.  Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies.

Authors:  Anne Proven; Rachelina P Bartlett; Kevin G Moder; April Chang-Miller; Laynalee K Cardel; John A Heit; Henry A Homburger; Tanya M Petterson; Teresa J H Christianson; William L Nichols
Journal:  Mayo Clin Proc       Date:  2004-04       Impact factor: 7.616

View more
  2 in total

Review 1.  Splanchnic Vein Thrombosis: Current Perspectives.

Authors:  Emanuele Valeriani; Nicoletta Riva; Marcello Di Nisio; Walter Ageno
Journal:  Vasc Health Risk Manag       Date:  2019-10-22

2.  Sigmoid Colon Varices due to Massive Thrombosis of a Noncirrhotic Extrahepatic Portosystemic Shunt.

Authors:  Manabu Hayashi; Tatsuro Sugaya; Masashi Fujita; Jun Nakamura; Hiromichi Imaizumi; Kazumichi Abe; Atsushi Takahashi; Tadayuki Takagi; Takuto Hikichi; Hiromasa Ohira
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.